First patient dosed in a Phase 3 clinical study of anti-HER2 biparatopic ADC JSKN003 for the treatment of HER2-positive breast cancer

CAR-T Digest - August 2020

Weekly Digest - February 2025

27 Feb 2025: First patient dosed in a Phase 3 clinical study of anti-HER2 biparatopic ADC JSKN003 for the treatment of HER2-positive breast cancer

Alphamab Oncology and CSPC have initiated a Phase 3 clinical study (JSKN003-301) to compare the efficacy and safety of the anti-HER2 biparatopic ADC JSKN003 with trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer
JSKN003, developed using Alphamab’s proprietary Glycan-specific conjugation platform, aims to improve therapeutic outcomes
The ADC demonstrates better serum stability, and a stronger bystander effect compared to its counterparts, potentially expanding its therapeutic window
In addition to JSKN003-301, Alphamab is conducting Phase 3 trials for JSKN003 in HER2 low-expressing breast cancer (JSKN003-302) and platinum-resistant ovarian cancer (JSKN003-306), with promising early results
Alphamab granted CSPC’s subsidiary, JMT-Bio, exclusive rights to develop and commercialize JSKN003 in mainland China, while Alphamab retains manufacturing rights